Aug 13, 2024 Cellectar Biosciences Reports Financial Results for Q2 2024 and Provides a Corporate Update Learn More
Aug 8, 2024 Cellectar Biosciences to Announce Second Quarter Financial Results and Host a Conference Call on Tuesday, August 13, 2024 Learn More
Jul 23, 2024 Cellectar Biosciences’ Iopofosine I 131 Exceeds Primary Endpoint in Waldenstrom’s Macroglobulinemia Pivotal Study with 78% of Major Response Patients Remaining Progression Free at 18 Months Learn More
Jul 22, 2024 Cellectar Biosciences Announces Exercise of Tranche B Warrants and Purchase of New Warrants for Approximately $19.4 million with the Potential to Raise Up to an Additional $73.3 Million Learn More